Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 9, 2000 - Issue 11
Submit an article Journal homepage
29
Views
9
CrossRef citations to date
0
Altmetric
Review

The association of infection and coronary artery disease: an update

Lisa Davydov Mount Sinai Medical Center, New York, NY, USA.
&
Judy WM Cheng Mount Sinai Medical Center, New York, NY, USA.
Pages 2505-2517 | Published online: 23 Feb 2005

Bibliography

  • GILLIUM RF: Trends in acute myocardial infarction and coronary heart disease death in United States. j Am. Coll. Cardiol (1994) 23:1273–1277.
  • LEVINE GN, KEANEY JF, VITA JA: Cholesterol reduction in cardiovascular disease. N. Engl. J Med. (1995) 332 (8):512–521.
  • SYKOWSKI PA, AGOSTINO RB, BELANGER AJ, KANNEL WB: Secular trends in long-term sustained hyperten-sion, long-term treatment and cardiovascular mortality. Circulation (1996)93:697–703.
  • BENDITT EP, BENDITT LJM: Evidence for a monoclonal origin of human atherosclerotic plaques. Proc. Natl. Acad. Sci. USA (1973)70:1753–1756.
  • MUHLESTEIN JB: Chronic infection and coronary artery disease. Med. Clin. North. Am. (2000) 84 (1):123–148.
  • SCHUSSHEIM AE, FUSTER V: Antibiotics for myocardial infarction? A possible role of infection in athero-genesis and acute coronary syndromes. Drugs (1999) 57 (3):283–291.
  • WIERZBICKI WB, HAGMEYER KO: Helicobacter pylori, Chlamydia pneumoniae and cy tomegalo virus: chronic infections and coronary heart disease Pharmacotherapy (2000) 20(0:52–63.
  • GIBBONS GH, DZAU VJ: The emerging concept of vascular remodeling. N. Engl. J. Med. (1994) 330 (20):1431–1438.
  • BASHA BJ, SOWERS JR: Atherosclerosis: an update. Am. Heart J. (1995) 131:1192–1202.
  • ZEIHER AM, DREXLER H, SAURBIER B, JUST H: Endothe-lium mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholes-terolemia and hypertension. j Clin. Invest. (1993) 92:652–662.
  • CHOBANIAN AV: Pathophysiology of atherosclerosis. Am. J. Card. (1992) 70(27):3G-7G.
  • DANGAS G, FUSTER V: Management of restenosis after coronary intervention. Am. Heart.] (1996)132:428–436.
  • LEE PC, GIBBONS GH, DZAU VJ: Cellular and molecular mechanisms of coronary artery restenosis. Coron. Artery Dis. (1993) 4(3):254–259.
  • ELLIS RW: Infection and coronary heart disease. J Med. Microbiol. (1997) 46:535–539.
  • DANESH J, COLLINS R, PETO R: Chronic infections and coronary heart disease: is there a link? Lancet (1997) 350:430–436.
  • GRAYSTON JT, CAMPBELL LA, KUO CC et al.: A newrespiratory tract pathogen: Chlamydia pneumoniae strain TWAIL J. Infect. Dis. (1990) 161:618–625.
  • LEINONEN M, LINNANMAKIAID E, MATTILA K et al.: Circulating immune complexes containing Chlamydia lipopolysaccharide in acute myocardial infarction. Microbic.] Pathol. (1990) 9:67–73.
  • LEINONEN M, LINNANMAKI E, MATTILA K, NIEMINEN MS,VALTONEN V, SAIKKU P: Chlamydia pneumoniae - specific circulating immune complexes in patients with chronic coronary heart disease. Circulation (1993) 87 :1130–1134.
  • SHOR A, KUO CC, PATTON DL: Detection of Chlamydiapneumoniae in coronary arterial fatty streaks and atheromatous plaques. S. Afr. Med. J. (1992) 82:158–161.
  • CAMPBELL LA, O'BRIEN ER, CAPPUCCIO AL et al.:Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect. Dis. (1995) 172:585–588.
  • JUVONEN J, JUVONEN T, LAURILA A et al.: Can degenera-tive aortic valve stenosis be related to persistent Chlamydia pneumoniae infection? Ann. Intern. Med. (1998) 128:741–744.
  • MILLER SA, SELZMAN CH, SHAMES BD et al.: Chlamydiapneumoniae activates nuclear factor KB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation. j Surg. Res. (2000) 90:76–81.
  • DECHEND R, MAASS M, GIEFFERS J et al.: Chlamydiapneumoniaeinfection of vascular smooth muscle and endothelial cells activates NF-KB and induces tissue factor and PAI-1 expression: A potential link to accelerated arteriosclerosis. Circulation (1999) 1 00:1369–1373.
  • MOLESTINA RE, MILLER RD, RAMIREZ JA, SUMMERSGILLJT: Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infect. Immun. (1999) 67(3):1323–1330.
  • KALAYOGLU MV, BYRNE GI: Induction of macrophagefoam cell formation by Chlamydia pneumoniae. J. Infect. Dis. (1998) 177:725–729.
  • KALAYOGLU MV, INDRAWATI, MORRISON RP, MORRISON SG, YUAN Y, BYRNE GI: Chlamydial virulence determinants in atherogenesis: The role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect. Dis. (2000) 181 (Suppl. 3):5483–S489.
  • KOL A, SUKHOVA GK, LICHTMAN AH, LIBBY P: Chlamy-dial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-a and matrix metalloproteinase expression. Circulation (1998) 98:300–307.
  • KALAYOGLU MV, HOERNEMAN B, LA VERDA D, MORRISON SG, MORRISON RP, BYRNE GI: Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J. Infect. Dis. (1999) 180:780–790.
  • HALME S, SYRJALA H, BLOIGU A et al.: lymphocyteresponses to chlamydia antigens in patients with coronary artery disease. Eur. Heart J. (1997) 1 8:1095–1101.
  • SAIKKU P: Chlamydia pneumoniaeand atherosclerosis-an update. Scand. J. Infect. Dis. (1997) (Suppl. 104):53–56.
  • SAIKKU P, LEINONEN M, MATTILA K et al: Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann. Intern. Med. (1992) 116:273–278.
  • SAIKKU P: Chlamydia pneumonia infection as a risk factor in acute myocardial infarction. Eur. Heart J (1993) 14 (Suppl. K):62–65.
  • GRAYSON JT, KUO CC, CAMPBELL! LA, BENDITT EP: Chlamydia pneumoniae, strain TWAR and atheroscle-rosis. Eur. Heart J. (1993) 14 (Suppl. K):66–71.
  • JACKSON LA, CAMPBELL LA, SCHMIDT RA et al.: Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: Evaluation of the innocent bystander hypothesis. Am. J. Pathol. (1997) 150:1785–1790.
  • KUO CC, SHOR A, CAMPBELL LA, FUKUSHI H, PATTONDL, GRAYSON JT: Demonstration of chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J. Infect. Dis. (1993) 167:841–849.
  • KUO CC, GOWN AM, BENDITT EP, GRAYSON JT: Detection of chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler. Thromb. (1993) 13:1501–1504.
  • KUO CC, GRAYSON JT, CAMPBELL LA, GOO YA, WISSLER RW, BENDITT EP: Chlamydia pneumoniae (TWAR) in coronary arteries in young adults (15 to 34 years). Proc. Natl. Acad. Sci. USA (1995) 92:6911–6914.
  • GRAYSON JT, KUO CC, COULSON AS et al: Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation (1995) 92:3397–3400.
  • MUHLESTEIN JB, HAMMOND EH, CARLQUIST JF et al.: Increased incidence of chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J. Am. Coll Cardiol (1996) 27:1555–1561.
  • DAVIDSON M, KUO CC, MIDDAUGH JP eta].: Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atheroscle-rosis. Circulation (1998) 98:628–633.
  • KUO CC, COULSON AS, CAMPBELL LA et al.: Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. Vasc. Surg. (1997) 26:29–31.
  • JACKSON LA, CAMPBELL LA, KUO CC et al.: Isolation of Chlamydia pneumoniae from a carotid endarterec-tomy specimen. J. Infect. Dis. (1997) 176:292–295.
  • SHOR A, PHILLIPS JI, ONG G et al.: Chlamydia pneumo-niae in atheroma: Consideration of criteria for causality. J. Clin. Pathol. (1998) 51:812–817.
  • MAASS M, BARTELS C, KRUGER S et al.: Endovascular presence of Chlamydia pneumoniae DNA is a general-ized phenomenon in atherosclerotic vascular disease. Atherosclerosis (1998) 140 (Suppl. 1):S25–S30.
  • MAASS M, GIEFFERS J, KRAUSE E et al.: Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients. Med. Microbic)]. Immunol. (1998) 187:103–106.
  • WONG Y, THOMAS M, TSANG V et al.: The prevalence ofChlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery. J Am. Coll. Cardiol. (1999) 33:152–156.
  • OUCHI K, FUJII B, KANAMOTO Y et al: Chlamydia pneumoniaein coronary and iliac arteries ofJapanese patients with atherosclerotic cardiovascular diseases. J. Med. Microbiol. (1998) 47:907–913.
  • JUVONEN J, JUVONEN T, LAURILA A et al.: Demonstra-tion of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc. Sing. (1997) 25:499–505.
  • YAMASHITA K, OUCHI K, SHIRAI M et al.: Distribution of Chlamydia pneumoniae infection in the atheroscle-rotic carotid artery. Stroke (1998) 29:773–778.
  • CHIU B: Multiple infections in carotid atherosclerotic plaques. Am. Heart J. (1999) 138:S534–S536.
  • PATERSON DL, HALL J, RASMUSSEN SJ et al.: Failure todetect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients. Pathology (1998) 30:169–172.
  • LINDHOLT JS, OSTERGARD J, HENNEBEREG EW et al.:Failure to demonstrate Chlamydia pneumoniae in symptomatic abdominal aortic aneurysms by a nested polymerase chain reaction (PCR). Eur.j Endovasc. Surg. (1998) 15:161–164.
  • OSSEWAARDE JM, FESKENS EJ, DE VRIES A et al.:Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helkobacter pylori and cytomegalovirus are not. Epidemic)]. Infect. (1998) 120:93–99.
  • GUPTA S, LEATHAM EW, CARRINGTON D et al.: Elevated Chlamydia pneumoniae ancardiovascularevents and azithromycin in male survivors of myocar-dial infarction. Circulation (1997) 96:404–407.
  • BLASE F, COSENTINI R, RACCANELLI R et al.: A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. Chest (1997) 112:309–312.
  • KARK JD, LEINONEN M, PALTIEL 0 et al.: Chlamydia pneumoniae and acute myocardial infarction in Jerusalem. Int. J. Epidemic)]. (1997) 26:730–738.
  • ANDERSON JL, CARLQUIST JF, MUHLESTEIN JB et al.: Evaluation of C-reactive protein, an inflammatory marker and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am. Coll. Cardiol. (1998) 32:35–41.
  • FAGERBERG B, GNARPE J, GNARPE H et al.: Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovas-cular disease: A prospective study in middle-aged to elderly men with treated hypertension. Stroke (1999) 30:299–305.
  • MIYASHITA N, TOYOTA E, SAWAYAMA T et al: Associa- tion of chronic infection of Chlamydia pneumoniae and coronary heart disease in the Japanese. Intern. Med. (1998) 37:913–916.
  • ALTMAN R, ROUVIER J, SCAZZIOTA A et al: lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease. Clin. Cardiol. (1999) 22:85–90.
  • RIDKER PM, KUNDSIN RB, STAMPFER MJ et al: Prospec-tive study of Chlamydia pneumoniae IgG seroposi-tivity and risks of future myocardial infarction. Circulation (1999) 99:1161–1164.
  • DANESH J, WONG Y, WARD M, MUIR J: Chronic infectionwith Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease. Heart (1999) 81:245–247.
  • WALD NJ, LAW MR, MORRIS JK, ZHOU X, WONG Y, WARD ME: Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ (2000) 321:204–207.
  • DANESH J, WHINCUP P, WALKER M et al.: LOW grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 321:199–204.
  • MOAZWS TC, KUO C, GRAYSON JT, CAMPBELL LA: Murine models of chlamydia pneumoniae infection and atherosclerosis. J Infect. Dis. (1997) 175:883–890.
  • FONG IW, CHIU B, VIRA E et al.: Rabbit model forChlamydia pneumoniae infection. J. Clin. Microbiol. (1997) 35:48–52.
  • LAITINEN K, LAURILA A, PYHALA L et al.: Chlamydiapneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect. Immun. (1997) 65:4832–4835.
  • MUHLESTEIN JB, ANDERSON JL, HAMMOND EF et al.:Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation (1998) 97:633–636.
  • FONG IW, CHIU B, VIIRA E, JANG D, MAHONY JB: De novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect. Immun. (1999) 67(11)6048–6055.
  • HUH, PIERCE GN, ZHONG G: The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. Clin. Invest. (1999) 103:747–753.
  • BRUGGEMAN C: Cytomegalovirus is involved invascular pathology. Am. Heart J. (1999) 138:S473–S475.
  • KOVACS A, WEBER M, BURNS L, JACOB H, VERCELOTTIG: Cytoplasmic sequestration of p53 in cytomegalovirus-infected human endothelial cells. Am. J. Pathol. (1996) 149:1531–1539.
  • CHENG JWM, RIVERA NG: Infection and atherosclerosis- focus on cytomegalovirus and Chlamydia pneumo-niae. Ann. Pharmacother. (1998) 32:1310–1316.
  • SEDMAK DD, KNIGHT DA, VOOK NC, WALDMAN JW: Divergent patterns of EIAM-1, ICAM-1 and VCAM-1 expression on cytomegalovirus-infected endothelial cells. Transplantation (1994) 58:1379–1385.
  • MELNICK JL, DEBAKEY ME: Cytomegalovirus and atherosclerosis. Eur. Heart J (1993) 14 (Suppl. K):30–38.
  • VAN DAM-MIERAS MC, BRUGGEMAN CA, MULLER AD, DEBIE WH, ZWAAL RF: Induction of endothelial cell procoag-ulant activity by cytomegalovirus infection. Thromb. Res. (1987) 47:69–75.
  • BENDITT EP: Implications of the monoclonal characterof human atherosclerotic plaques. Am. J Pathol. (1977) 86:693–702.
  • TANAKA K, ZOU JP, TAKEDA K et al.: Effects of humancytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. Circulation (1999) 99: 1656-1659.
  • LIBBY P, EGAN D, SKARLATOS S: Roles of infectiousagents in atherosclerosis and restenosis. Circulation (1997) 96:4095–4103.
  • MELNICK J, ADAM E, DEBAKEY M: Possible role ofcytomegalovirus in atherogenesis. JAMA (1990) 263(16)2204–2207.
  • ZHOU YF, LEON MB, WACLAWIW MA et al: Associationbetween prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl. J Med. (1996) 335:624–630.
  • SORLIE PD, NIETO FJ, ADAM E et al.: A prospective studyof cytomegalovirus, herpes simplex virus 1 and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arch. Intern. Med. (2000) 160:2027–2032.
  • ROTHENBACHER D, HOFFMEISTER A, BODE G et al.: Cytomegalovirus infection and coronary heart disease: Results of a German case-control study. J Infect. Dis. (1999) 179:690–692.
  • ADLER SP, HUR JK, WANG JB et al.: Prior infection withcytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J. Infect. Dis. (1998) 177:209–212.
  • MANEGOLD C, ALWAZZEH M, JABLONOWSKI H et al.: Prior cytomegalovirus infection and the risk of restenosis after percutaneous transluminal coronary balloon angioplasty. Circulation (1999) 99:1290–1294.
  • DANESH J, COLLINS R, PETO R: Chronic infections andcoronary heart disease: is there a link? Lancet (1997) 350:430–436.
  • KOSKINEN P, LEMSTROM K, BRUGGEMAN C, LAUTENSCHLAGER I, HAYRY P: Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in allograft arteriosclerosis. Am. J Pathol. (1994) 144:41–50.
  • GRATTAN M, MORENO-CABRAL1 C, VAUGHN A, OYER P, STINSON EB, SHUMWAY NE: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA (1989) 261:3561–3566.
  • KUSTERS JG, KUIPERS EJ: Helicobacter and atheroscle-rosis. Am. Heart J. (1999) 138:S523–S527.
  • MARKLE HV: Coronary artery disease associated with Helkobacter pyloriinfection is at least partially due to inadequate folate status. Med. Hypotheses (1997) 49:289–292.
  • PASCERI V, CAMMAROTA G, PATTI G et al: Associationof virulent Helkobacter pylori strains what ischemic heart disease. Circulation (1998) 97:1675–167.
  • WALD NJ, LAW MR, MORRIS JK, BAGNALL AM: Helico-barter pylori infection and mortality from ischaemic disease: Negative result from a larger, prospective study. BMJ (1997) 315:1199–1201.
  • FONG IW, CHIU B, VIRA E et al.: Can an antibiotic(macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model? Clin. Diagn. Lab. Immunol. (1999) 6(6):891–894.
  • GURFINKEL E, BOZOVICH G, DAROCA A et al.: Random-ized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot study. ROXIS Study Group. Lancet (1997) 350:404–407.
  • ANDERSON JL, MUHLESTEIN JB, CARLQUIST J et al: Randomized secondary prevention trial of azithro-mycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of myocardial infection with Chlamydia (ACADEMIC) Study. Circulation (1999) 99:1540–1547.
  • MEIER CR, DERBY LE, JICK SS, VASILAKIS C, JICK H: Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA (1999) 281 (5):427–431.
  • JACKSON LA, SMITH NL, HECKBERT SR, GRAYSTON JT,SISCOVICK DS, PSATY BM: lack of association between first myocardial infarction and past use of erythro-mycin, tetracycline, or doxycycline. Emerg. Infect. Dis. (1999) 5 (2):281–284.
  • HOPKINS S: Clinical toleration and safety of azithro-mycin. Am. J. Med. (1991) 91 (Suppl. 3A):405–455.
  • FOULDS G, SHEPARD RM, JOHNSON RB: The pharma-cokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. (1990) 25 (Suppl. A):73–82.
  • KITA E, SAWAKI M, MIKASA K et al.: Alteration of host response by long-term treatment of roxithromycin. Antimicrob. Chemother. (1993) 32:285–294.
  • GURFINKEL E, BOZOVICH G, BECK E et al.: Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur. Heart J. (1999) 20:121–127.
  • DUNNE MW: Rationale and design of a secondary prevention trial of antibiotic use in patients after myo car dial infarction: The WIZARD (Weekly Interven-tion with Zithromax [Azithromycin] for Atheroscle-rosis and Its Related Disorders) trial./ Infect. Dis. (2000) 181:S572–S578.
  • GRAYSTON TJ, JACKSON LA, KENNEDY WJ, KRONMAL RA: Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: Design issues. Am. Heart J. (1999) 138:S545–S549.
  • VALANTINE HA, GAO SZ, MENON SG et al.: Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis. Circulation (1999) 100:61–66.
  • MAASS M, JAHN J, GIEFFERS J, DALHOFF K, KATUS HA, SOLBACH W: Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. J. Infect. Dis. (2000) 181 (Suppl. 3):S449–S451.
  • SHAFRAN SD, CONLY JM: Does C. pneumoniae cause coronary atherosclerosis and should we all take macrolides? Can. J. Cardiol. (1997) 13(10:1017–1019.

Websites

  • http://www.nhlbi.nih.gov/nihlbi/news/premv.txt Liya Davydov & Judy WM Chengt

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.